个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Neoadjuvant QL1209 (a pertuzumab biosimilar) compared with pertuzumab plus trastuzumab and docetaxel in early or locally advanced, HER2-positive, ER(-)/PR(-) breast cancer: A multicenter, randomized, double-blind, equivalence, phase III study

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Shao, Z.[1] * ; Zhang, J.[2] ; Qian, J.[3] ; Ma, X.[4] ; Niu, Z.[5] ; Ou, J.[6] ; Mo, Q.[7] ; Sun, J.[8] ; Li, X.[9] ; Wang, Q.[10] ; Yao, Y.[11] ; Yu, G.[12] ; Li, H.[13] ; Chen, D.[14] ; Zhang, H.[15] ; Geng, C.[16] ; Qiao, G.[17] ; Zhao, M.[18] ; Zhang, B.[19] ; Kang, X.[18] ;
机构： [1]Fudan Univ, Breast Surg Dept, Shanghai Canc Ctr, Shanghai, Peoples R China [2]Tianjin Med Univ Canc Inst & Hosp, Breast Oncol Dept 3, Tianjin, Peoples R China [3]Bengbu Med Coll, Dept Surg Oncol, Affiliated Hosp 1, Bengbu, Peoples R China [4]USTC, Affiliated Hosp 1, Anhui Prov Hosp, Genl Surg Dept,Ctr Creast & Thyroid, Hefei, Peoples R China [5]Yuncheng Cent Hosp, Breast Dis Dept, Yuncheng, Peoples R China [6]Xinjiang Med Univ, Breast Surg Dept, Canc Hosp, Xinjiang, Peoples R China [7]Guangxi Med Univ Canter Hosp, Breast Surg Dept, Nanning, Peoples R China [8]Anyang Tumour Hosp, Breast Med Dept, Anyang, Peoples R China [9]Shanxi Canc Hosp, Breast Surg Dept, Taiyuan, Peoples R China [10]Qingdao Univ, Breast Surg Dept 1, Qingdao Cent Hosp, Qingdao, Peoples R China [11]Nanjing Univ, Breast Surg Dept, Affiliated Hosp, Sch Med, Nanjing, Peoples R China [12]Weifang Peoples Hosp, Dept Med Oncol, Weifang, Kuiwen District, Peoples R China [13]Guangzhou Med Univ, Breast Surg Dept, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China [14]Yunnan Canc Hosp, Breast Surg Dept 2, Kunming, Yunnan, Peoples R China [15]Nanyang Cent Hosp, Breast Surg Dept, Nanyang, Peoples R China [16]Hebei Med Univ, Hebei Tumor Hosp, Breast Ctr, Hosp 4, Shijiazhuang, Hebei, Peoples R China [17]Yantai Yuhunagding Hosp, Breast Surg Dept, Yantai, Shangdong, Peoples R China [18]Qilu Pharmaceut Co Ltd, Dept Med, Jinan, Peoples R China [19]Qilu Pharmaceut Co Ltd, Stat & Stat Programming, Jinan, Peoples R China
出处：
DOI： 10.1016/j.annonc.2023.09.443
ISSN：
基金：
Qilu Pharmaceutical Co., Ltd.
语种：
外文
WOS：
中科院分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2024]版：
Q1 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者：
第一作者机构： [1]Fudan Univ, Breast Surg Dept, Shanghai Canc Ctr, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Shao Z.,Zhang J.,Qian J.,et al.Neoadjuvant QL1209 (a pertuzumab biosimilar) compared with pertuzumab plus trastuzumab and docetaxel in early or locally advanced, HER2-positive, ER(-)/PR(-) breast cancer: A multicenter, randomized, double-blind, equivalence, phase III study[J].ANNALS OF ONCOLOGY.2023,34:S281-S281.doi:10.1016/j.annonc.2023.09.443.
APA：
Shao, Z.,Zhang, J.,Qian, J.,Ma, X.,Niu, Z....&Kang, X..(2023).Neoadjuvant QL1209 (a pertuzumab biosimilar) compared with pertuzumab plus trastuzumab and docetaxel in early or locally advanced, HER2-positive, ER(-)/PR(-) breast cancer: A multicenter, randomized, double-blind, equivalence, phase III study.ANNALS OF ONCOLOGY,34,
MLA：
Shao, Z.,et al."Neoadjuvant QL1209 (a pertuzumab biosimilar) compared with pertuzumab plus trastuzumab and docetaxel in early or locally advanced, HER2-positive, ER(-)/PR(-) breast cancer: A multicenter, randomized, double-blind, equivalence, phase III study".ANNALS OF ONCOLOGY 34.(2023):S281-S281

资源点击量：42329 今日访问量：0 总访问量：1365 更新日期：2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号